What is Moderna?
Moderna is at the forefront of mRNA therapeutics and vaccines, leveraging a unique blend of scientific innovation and advanced technology to address a spectrum of diseases. The company's work spans infectious conditions, oncology, rare disorders, and autoimmune challenges, aiming to create impactful and lasting solutions. Its distinctive culture and global team are dedicated to advancing human health through novel mRNA-based medicines.
How much funding has Moderna raised?
Moderna has raised a total of $8.1B across 19 funding rounds:
Other Financing Round
$25M
Other Financing Round
$450M
Multiple Rounds
$502M
Multiple Rounds
$1.2B
Multiple Rounds
$2.8B
Other Financing Round
$750M
Multiple Rounds
$2.1B
Other Financing Round (2014): $25M featuring Alexion Pharmaceuticals
Other Financing Round (2015): $450M backed by AstraZeneca, Alexion Pharmaceuticals, Invus, RA Capital Management, Wellington Management, and Viking Global Investors
Grant (2016): $20M with participation from Bill & Melinda Gates Foundation
Grant (2016): $8M led by BARDA
Other Financing Round (2016): $474M supported by AstraZeneca, Invus, Alexion Pharmaceuticals, Wellington Management, RA Capital Management, and Viking Global Investors
Other Financing Round (2018): $500M featuring ADIA, ArrowMark Partners, BB Biotech Ventures, Sequoia Capital China, Fidelity Management & Research Company, Julius Baer Group, Alexandria Venture Investments, Pictet Private Equity Investors S.A., EDBI, and Viking Global Investors
Corporate Investment (2018): $125M backed by Merck
Stock Issuance/Offering (2018): $604.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $500M, investors not publicly disclosed
Grant (2020): $483M supported by BARDA
Stock Issuance/Offering (2020): $1.3B, investors not publicly disclosed
Grant (2020): $472M, investors not publicly disclosed
Other Financing Round (2024): $750M with participation from Blackstone
Other Financing Round (2025): $590M led by Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $1.5B supported by Ares Management Corporation
Unspecified (2025): $54.3M, investors not publicly disclosed
Key Investors in Moderna
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
Flagship Ventures
Founded in 1999 and headquartered in Cambridge, Massachusetts, Flagship Pioneering is a company of pioneering scientists and professionals that build companies that transform human health and sustainability.
AstraZeneca
AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca is based in the United Kingdom.
What's next for Moderna?
With a history of substantial enterprise-level funding and strategic investments, Moderna is well-positioned for continued expansion and innovation. The company's ongoing development of mRNA-based therapies suggests a trajectory focused on scaling its research and development capabilities, potentially exploring new therapeutic areas and expanding its global reach. Future capital infusions will likely support clinical trials, manufacturing scale-up, and the commercialization of its pipeline, solidifying its leadership in the biotechnology sector.
See full Moderna company page
